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The purpose of this paper was to evaluate the eﬃcacy of topical skin lipid complex (SLC) in canine atopic dermatitis (AD). Eight
dogs with chronic AD and no improvement of main therapy in symptoms, erythema, licheniﬁcation, excoriation, and alopecia
in the previous month were treated with SLC topically as adjunct therapy at lesion sites twice weekly for 12 weeks. A statistically
signiﬁcant reduction (26.0%, P<0.05) in the third version of the Canine Atopic Dermatitis Extent and Severity Index (CADESI-
03) modiﬁcation from baseline was recorded 6 weeks after treatment, with marked reduction in the erythema subscore (36.2%,
P<0.005). A signiﬁcant reduction in excoriation and alopecia subscores was observed 6 weeks after treatment (39.9%, P<0.05
and 19.9%, P<0.05, resp.). However, the licheniﬁcation subscore was not reduced signiﬁcantly at 6 or 12 weeks. These ﬁndings
suggest that topical SLC may have therapeutic and clinical beneﬁts in dogs with AD.
1.Introduction
Atopic dermatitis (AD) is a common allergic skin disease
in both people and dogs. The clinical signs of canine AD
are variable, and the diagnosis of canine AD is made by
eliminating other causes of pruritus; the diagnosis is one of
exclusion [1]. The treatment of dogs with AD is complex
and lifelong and involves multiple modalities depending on
the severity of clinical signs, the dog’s response to medical
therapy, and whether clinical signs are seasonal or perennial
[1]. In people with AD, a study has shown impairment of
the skin barrier function and abnormal lipid production [2].
In one human study, the application of a topical moisturizer
containing ceramides produced dramatic improvement in
clinical scores after 3 and 6 weeks of treatment [3]. In
dogs with AD, electron microscopy (EM) revealed sparse
and disorganized lamellar lipids (LLs) and deﬁciencies of
the stratum corneum intercellular lipids [4]. This ﬁnding
suggests that similar defects or abnormalities of the skin
barrier may be involved in the pathogenesis of canine AD. In
dogs with AD, the application of a topical skin lipid complex
(SLC) led to improvements in intercorneocyte structure,
production of LLs, and ﬁlling of intercorneocyte spaces with
newly formed LLs, as shown by EM [5]. In another study,
it was suggested that decreased amounts of ceramides and
increased cholesterol content may be involved in epidermal
barrier dysfunction [4]. In addition, correlations were found
between transepidermal water loss and relative ceramide
content in both lesional and nonlesional skin of dogs
with AD [6]. ALLERDERM Spot-On (Virbac SA, Carros,
France) is a topical spot-on skin lipid therapy that contains
ceramides, cholesterol, and free fatty acids. The goal of this
study was to evaluate the clinical beneﬁts of topical SLC in
the treatment of dogs with chronic AD by using the third
version of the Canine Atopic Dermatitis Extent and Severity
Index (CADESI-03) modiﬁcation.2 Veterinary Medicine International
Table 1: Characteristics of dogs at enrollment in the study.
No. Age at entry in
the study (months)
Age at onset of AD
(months) Breed Sex Reacting
antigen
Combination therapy
Immunotherapy
(duration
(months))
Immunomodulating
drugs
19 6 1 2 Welsh Corgi
Pembroke Mc HDM + (36) Pentoxifylline
2 96 36 Maltese Fs HDM + (31) Pentoxifylline
3 144 36 Shiba inu Fs HDM + (34)
4 24 12 Chihuahua Fs Cotton
Linters +( 7 )
5 36 12 WHWT Fs HDM + (14)
6 36 12 Pug Fs HDM + (6)
7 108 24 Shiba inu F HDM + (31 ) Pentoxifylline
8 108 24 Yorkshire Terrier F HDM —
WHWT: West Highland White Terrier, Mc: castrated male, Fs: spayed female, F: female, HDM: House Dust Mite Mix (Dermatophagoides farinae,
Dermatophagoides pteronyssinus).
+: immunotherapy administration. —: no immunotherapy.
2.MaterialsandMethods
2.1. Animals. The investigators recruited 8 dogs from their
hospital with a diagnosis of nonseasonal AD and persistent
pruritus despite therapy. The breed, sex, age, and age of
disease onset of the 8 dogs aregiven inTable 1. The ageof the
dogs at entry in the study was 2–12 years (mean: 6.75 years).
The age of disease onset was 1–3 years (mean: 1.75 years).
Two female dogs, 5 spayed female dogs, and 1 castrated
male dog were included in the study. This open clinical trial
was conducted between September 2009 and December 2009
with the owner’s informed consent.
2.2. Pretreatment Assessment. The diagnosis of AD was
made by ruling out other causes of pruritus. Dogs were
negativefordemodicosisbaseduponnegativeskinscrapings.
The dogs underwent rigorous ﬂea control and appropriate
treatment for contagious parasitic mites. Bacterial pyoderma
and yeast overgrowth (Malassezia dermatitis) were treated, if
present.Finally,alldogsunderwentaneliminationdietusing
“hypoallergenic” foods (Hill’s prescription diet canine z/d
Ultra: Hill’s Pet Nutrition, Topeka, KS, USA; or Royal Canin
Veterinary Diet Sensitivity Control: Royal Canin, Aimargue,
France; or Iams Veterinary Formulas FP: Cincinnati, Ohio,
USA) for at least 8 weeks with no improvement. The
diagnosis of AD was based upon elimination of other causes
ofpruritus,compatiblehistory,andcompatibleclinicalsigns,
as well as Willemse’s criteria for the diagnosis of nonseasonal
AD [7]. Intradermal allergy testing was performed with
24 selected antigens (Greer Pharmacy, Lenoir, NC, USA;
or TORII Pharmaceutical co., Ltd., Tokyo, Japan). Seven
dogs had positive reactions to house dust mite mix (Der-
matophagoides farinae and D. pteronyssinus) and 1 dog had
positive reactions to cotton (Table 1).
2.3. SLC. A topical SLC product containing ceramides,
cholesterol, and free fatty acids (ALLERDERM Spot-On;
Virbac SA, Carros, France) was applied at a dose of
2mL twice weekly, by applying several drops on the head,
interscapular area, and directly on lesion sites.
2.4. Concurrent Treatments. Allergen-speciﬁc immunother-
apy and/or immunomodulating drugs such as pentoxifylline
were continued as a combination therapy for Dogs 1–
7( Table 1). Seven dogs were receiving allergen-speciﬁc
immunotherapy for 6 to 36 months prior to inclusion in
the study. Three of these 7 dogs were also receiving long-
term oral pentoxifylline for the management of pruritus.
Assessments were performed 4 weeks prior to starting the
study to ensure that there was no improvement in clinical
signs from any concurrent therapies. No other therapies
(e.g., corticosteroids, cyclosporine, and antimicrobial) were
allowed during the 12-week treatment period.
2.5. CADESI-03 Modiﬁcation. CADESI-03 modiﬁcation was
used to assess lesion severity. The severity of erythema,
licheniﬁcation, excoriations, and alopecia was assessed at
33 body sites using a scale from 0–5 (0 = none, 1 =
mild, 2-3 = moderate, and 4-5 = severe). In CADESI-03,
the severity of erythema, licheniﬁcation, excoriation, and
alopecia was assessed at 62 body sites by using a scale from
0t o5[ 8]. CADESI-03 modiﬁcation was simpliﬁed to assess
each symptom at 33 body sites. Total score of CADESI-03
modiﬁcation was 660 while that of CADESI-03 was 1240.
Dogs were scored 4 times during the study: 4 weeks prior to
therapy and at week 0, week 6, and week 12 of therapy. The
same investigator performed all assessments.
2.6. Statistical Analysis. Statistical analysis was performed
by use of paired t-tests with SAS 8.2 software. Statistical
signiﬁcance was deﬁned as P<0.05. In this study, the mean
data for total scores and subscores were pooled at each time
point and compared to the other assessment periods.Veterinary Medicine International 3
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Figure 1: (a) CADESI-03 modiﬁcation total score improved 6 weeks (D0 + 6W) and 12 weeks (D0 + 12W) after starting treatment (D0)
with topical SLC. Results are expressed as mean, n = 7. ∗P<0.05, compared with D0 score. Number below the abscissa axis indicates
average diﬀerence rate (%) from D0. (b) Erythema improved dramatically during the trial period. Results are expressed as mean, n = 7.
∗P<0.05, ∗∗∗P<0.005, compared with D0 score. Number below the abscissa axis indicates average diﬀerence rate (%) from D0. (c) Mean
licheniﬁcation subscore. Results are expressed as mean, n = 7. Number below the abscissa axis indicates average diﬀerence rate (%) from
D0. (d) Excoriation improved during the trial period. Results are expressed as mean, n = 7. ∗P<0.05, compared with D0 score. Number
below the abscissa axis indicates average diﬀerence rate (%) from D0. (e) Alopecia improved during the trial period. Results are expressed as
mean, n = 7. ∗P< 0.05, compared with D0 score. Number below the abscissa axis indicates average diﬀerence rate (%) from D0.
3. Results
Neithertheownersnortheinvestigatorsreportedanyadverse
reactions to the application of the SLC therapy. Eight dogs
were entered into the study; however, 1 dog was not included
in the data analysis, because of a signiﬁcant increase in
pruritusatthestartofthestudy.Theownerhaddiscontinued
immunotherapy just after starting the study; this was a
deviation from the study protocol and the dog was excluded
(Dog 6). Clinical data are summarized in Table 1.F e m a l e
dogs were overrepresented in the study. Dogs ranged in age
from 2–12 years (mean 6.75 years). No signiﬁcant change in4 Veterinary Medicine International
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Figure 2: Clinical characteristics of Dog 5 at start of the treatment (D0), 6 weeks after D0, and 12 weeks after treatment are shown in
Figures 2(a), 2(b),a n d2(c), respectively. Progressive changes in disease severity were seen in the 12-week trial period. The dog was treated
continuously after the completion of the trial. Clinical symptoms improved 18 weeks after D0 (Figure 2(d)).
each subscore was found between the 4-week pre-treatment
assessment and week 0 (P>0.05). When CADESI-03
modiﬁcation total scores at week 0 were compared to those
at 6 weeks after treatment, a signiﬁcant decrease in scores
was noted (26.0%, P<0.05). No signiﬁcant diﬀerence was
found between CADESI-03 modiﬁcation total score at week
6 and week 12. Erythema was the parameter most reduced in
the trial period (week 6: 36.2%, P<0.005; week 12: 46.3%,
P<0.05) whereas the licheniﬁcation score was reduced, but
not signiﬁcantly (week 6: 14.4%, P>0.05; week 12: 43.3%,
P>0.05).Therewasadecreaseinexcoriationsubscore(week
6: 39.9%, P<0.05; week 12: 72.0%, P>0.05) and alopecia
subscore(week6:19.9%,P<0.05;week12:30.5%,P>0.05)
from week 0 to week 6 or week 12 (Figures 1(a) to 1(e)).
Nosigniﬁcantdiﬀerenceofeachsubscorewasfoundbetween
week 6 and week 12. Progressive changes in Dog 5 over the
12-week period are shown in Figures 2(a) to 2(d).
4. Discussion
It is diﬃcult to demonstrate the clinical eﬃcacy of the SLC
spot-on treatment in atopic dogs in clinical practice, because
topicallipidapplicationsarenotusedasmonotherapy.These
formulations are intended to be used as adjunct therapies
in combination with other anti-inﬂammatory drugs, antimi-
crobial drugs, and immunotherapy as part of the global
approach to the management of canine AD. In this study, the
investigators found no change in disease severity attributed
to the underlying anti-allergic treatment (allergen-speciﬁc
immunotherapy or oral pentoxifylline administration) in
the month prior to inclusion, based upon the unchanged
CADESI-03 modiﬁcation subscores. Immunotherapy was
continuously performed for 7 dogs during 36, 31, 34, 7, 14,
6 ,a n d3 1m o n t h sf o rD o g s1 ,2 ,3 ,4 ,5 ,6 ,a n d7 ,r e s p e c t i v e l y .
H D Mf o rD o g s1 ,2 ,3 ,5 ,6 ,7 ,a n d8a n dc o t t o nl i n t e r sf o r
Dog 4 were identiﬁed as the reacting antigen by skin test for
intracutaneous reactivity. Because all dogs were aﬀected with
nonseasonal AD, it was considered that the treatment period
from September to December had no inﬂuence on the skin
test result.
During the 12-week treatment period, however, the total
clinical score progressively decreased; decreasing scores are
associated with an improvement in clinical signs. The change
in the scores for excoriations and erythema was the most
dramatic. Because the only change in treatment over the
12 weeks was the addition of the SLC spot-on therapy,
these results suggest that topical lipids may play a role in
the reduction of inﬂammation. Piekutowska et al. suggested
that SLC spot-on contributed to the formulation of an
improved epidermal barrier, as shown by EM [5]. Repair of
epidermal barrier function presumably lead to the reduction
in inﬂammation seen in this study.
In the study reported here, the maximum decrease in
the erythema subscore was noted by week 6; in contrast,
there was a continued decrease in subscores for excoriations
and alopecia. Erythema is a hallmark of inﬂammation. If
inﬂammation is stabilized, it follows that self-trauma will
decrease. The continued decrease in the scores for alopecia
is most likely related to the lack of self-trauma and regrowthVeterinary Medicine International 5
of hair. The lack of further reductions in the CADESI-
03 subscore between week 6 and week 12 of topical SLC
treatment is similar to results of a study in people with AD
using a topical ceramide-based emollient [3]. Interestingly,
in the human study, a subsequent reduction in the frequency
of use of the ceramide emollient was associated with a
reincrease of the clinical score [3].
Topical lipid applications are not eﬀective as monother-
apy, nor are they designed for this use. In people with AD,
it has been shown that routine use of a topical physiologic
lipid emollient can delay the need for topical glucocorticoid
therapy [9]. Our ﬁndings are encouraging, but double-
blinded placebo-controlled or cross-over studies are needed
to conﬁrm our results. In addition, the drug-sparing eﬀects
of SLC applications also deserve further investigation.
5. Conclusions
In conclusion, the results of this study suggest that topical
SLC application is beneﬁcial when used in the management
of canine AD.
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